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In  a project  to characterise  new  antibacterial  chemotypes  from  plants,  hyperenone  A and  hypercalin  B
were  isolated  from  the  hexane  and  chloroform  extracts  of  the  aerial  parts  of  Hypericum  acmosepalum.
The  structures  of  both  compounds  were  characterised  by  extensive  one-  and  two-dimensional  nuclear
magnetic  resonance  (NMR)  spectroscopy  and  were  conﬁrmed  by  mass  spectrometry.  Hyperenone  A
and  hypercalin  B  exhibited  antibacterial  activity  against  multidrug-resistant  strains  of Staphylococcus
aureus,  with  minimum  inhibition  concentration  ranges  of  2–128  mg/L  and  0.5–128  mg/L,  respectively.ypercalin  B
taphylococcus aureus
uberculosis
eptidoglycan
urE  ligase
Hyperenone  A  also  showed  growth-inhibitory  activity  against  Mycobacterium  tuberculosis  H37Rv  and
Mycobacterium  bovis  BCG  at 75  mg/L  and  100  mg/L.  Neither  hyperenone  A  nor hypercalin  B inhibited
the  growth  of Escherichia  coli and  both  were  non-toxic  to cultured  mammalian  macrophage  cells.  Both
compounds  were  tested  for their  ability  to inhibit  the  ATP-dependent  MurE  ligase  of  M.  tuberculosis,  a
crucial  enzyme  in  the  cytoplasmic  steps  of  peptidoglycan  biosynthesis.  Hyperenone  A inhibited  MurE
selectively,  whereas  hypercalin  B  did  not  have  any  effect  on  enzyme  activity.. Introduction
In recent years, drug resistance in Mycobacterium tuberculosis
nd other clinically relevant bacterial pathogens such as meticillin-
esistant Staphylococcus aureus (MRSA) has emerged as a major
hreat to public health, with severe economic and social implica-
ions [1,2]. MRSA is still one of the most widespread and virulent
osocomial pathogens in the world [3] and is usually resistant
o multiple antibiotics, making infection difﬁcult to treat, and
ccounts for an increased proportion of staphylococcal infections
mongst hospitalised patients in countries where it has become
stablished. Despite new advances in antibiotic development, with
gents such as linezolid, daptomycin and quinupristin/dalfopristin
ppearing over the last decade [4], MRSA infections still remain
f considerable concern owing to resistance to some of these new
rugs [5,6].
Tuberculosis (TB) is caused predominantly by M.  tuberculosis,
n obligate aerobic pathogen that divides at an extremely slow
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rate. The World Health Organization estimates that 2 billion peo-
ple have latent TB whilst another 2 million people die of TB each
year worldwide [7]. Although TB is generally treatable, the expo-
nential emergence of extensively drug-resistant or completely
drug-resistant TB strains is a current global health emergency
where there is virtually no treatment available [8]. Therefore, new
antibacterial agents with novel modes of action are urgently needed
to meet the challenge posed by these resistant variants.
The peptidoglycan biosynthesis pathway is a validated target
for the development of antibacterial agents, including the classi-
cal -lactam, cephalosporin and glycopeptide antibacterials [9].
The peptidoglycan layer of the cell wall serves as a base for the
lipid-rich capsule. Peptidoglycan (or murein) is the polymeric mesh
of the bacterial cell wall that plays a vitally important role in
protecting bacteria against osmotic lysis. Peptidoglycan biosynthe-
sis can be separated into two  phases, comprising six intracellular
enzymatic steps and three steps that occur outside of the plasma
membrane [10]. Amongst the cytoplasmic steps involved in the
biosynthesis of peptidoglycan, four ATP-dependent ligases (MurC,
MurD, MurE and MurF) catalyse the assembly of its peptide moi-
Open access under CC BY license.ety by successive additions of l-alanine, d-glutamate, a diamino
acid [usually meso-diaminopimelic acid (m-DAP) or l-lysine] and
d-alanine–d-alanine to UDP N-acetylmuramic acid (MurNAc) [11].
Although most antimicrobials target steps in the later stage of cell
ess under CC BY license.
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Table 1
Nuclear magnetic resonance (NMR) [500 MHz  (1H) and 125 MHz  (13C)] data for
hyperenone-A  (2) in CDCl3.
Position 1H ı ppm (J) 13C ı ppm
2 157.1
3 111.7
4 181.4
5 6.61 111.5
6 162.9
1 131.1
2′ , 6′ 7.70 m 125.4
3′ , 5′ 7.48 m 129.3
4′ 7.47 m 131.0
1′′ 39.0
2′′ 6.25 dd (17.2, 10.4) 148.5
3′′ 4.90 d (17.2)4.95 d (10.4) 108.5K. Osman et al. / International Journal
all biosynthesis, the earlier steps in peptidoglycan biosynthesis
ave recently received renewed attention in terms of novel thera-
eutic targets [12]. To date, only fosfomycin, which targets MurA
NAG enolpyruvate transferase), has been developed as an antibac-
erial agent targeting early biosynthesis of cell wall peptidoglycan
10,11]. The enzymes involved in the peptidoglycan biosynthetic
athway are characteristic of Eubacteria and are absent in humans.
hese enzymes are therefore excellent targets for anti-infective
rug development.
Although most antibiotics in clinical use have been obtained
rom microorganisms, an interest in plant antibacterials has re-
merged during the last three decades. Of the known plant species
estimated at 250 000), only a very small fraction has been inves-
igated for the presence of antibacterial compounds and an even
maller number of these phytochemicals have been subjected to a
odern rigorous pharmacological evaluation of their antibacterial
roperties.
Species of the plant genus Hypericum are used in traditional
edicine for their therapeutic value [13]. Hypericum perforatum
. (commonly known as St John’s Wort) is the most investigated
ember of the genus both from the perspective of chemical con-
tituents and biological activity [14]. It has been used extensively
n herbal medicine as an antidepressant [14], for various skin treat-
ents such as eczema, wounds and burns, as well as in disorders
f the alimentary tract, amongst others [14].
Hypericum acmosepalum is a shrub of 0.6–2 m in height with
eep-yellow petals that are sometimes tinged red. It is cultivated
s an ornamental shrub in many parts of the world, but particularly
n Great Britain [15]. Previous studies on H. acmosepalum are lim-
ted, with some ethnobotanical usage by the Yao People of Yunnan
rovince in China [16]. Here we describe the isolation, structural
lucidation and antibacterial action of two natural products from
. acmosepalum. Their ability to inhibit the ATP-dependent MurE
igase enzyme from M.  tuberculosis [10], a pivotal enzyme in pepti-
oglycan biosynthesis, was also assessed.
. Materials and methods
.1.  Bacterial strains
A  standard S. aureus strain (ATCC 25923) as well as a clinical iso-
ate (XU212) that possesses the Tet(K) efﬂux pump and is also an
RSA strain were obtained from Dr Edet Udo (Kuwait University)
17]. Epidemic MRSA types 15 and 16 (EMRSA-15 and EMRSA-16)
ere provided by Dr Paul Stapleton (The School of Pharmacy, Uni-
ersity of London, UK). Strain SA-1199B that overexpresses the
orA multidrug resistance efﬂux pump was donated by Prof. Glenn
. Kaatz (Wayne State University, Detroit, MI)  [18]. Strain RN4220
hat has the MsrA macrolide efﬂux pump was a generous gift from
r Jon Cove (University of Leeds, UK) [19]. Mycobacterium bovis
CG (ATCC 35734) and RAW 264.7 (a mouse leukaemic monocyte
acrophage cell line) were obtained from Prof. Siamon Gordon (Sir
illiam Dunn School of Pathology, University of Oxford, Oxford,
K). Mycobacterium tuberculosis H37Rv (ATCC 9360) was  purchased
rom the Health Protection Agency (Porton Down, Salisbury, UK).
.2. Isolation of compounds
Hypericum  acmosepalum was collected from the National Hyper-
cum Collection at the Royal Botanic Gardens, Kew (Ardingly, UK)
n August 2005. The authenticity of this species has been veriﬁed
y Dr N.K.B. Robson. Voucher specimens of these collections have
een deposited at the Department of Pharmaceutical and Biolog-
cal Chemistry (SG-2005-2/6) (School of Pharmacy, University of
ondon, London, UK). Dried and powdered material (500 g) of H.4′′/5′′ 1.50 27.7
MeO 4.06 56.2
acmosepalum was  extracted sequentially in a Soxhlet apparatus
(Fisher Scientiﬁc, Loughborough, UK) using 3.5 L of organic sol-
vents of increasing polarity (hexane, chloroform and methanol).
Vacuum-liquid chromatography (VLC) (Silica gel 60 PF254+366;
Merck, Darmstadt, Germany) was  performed on 6.3 g of the hexane
extract with an increasingly polar gradient of 10% increments, from
100% hexane to 100% ethyl acetate, yielding 12 fractions. Thin-layer
chromatography (TLC) of Fraction 6 showed a major compound
that was subjected to LH-20 Sephadex column chromatography
(Sigma Aldrich, Gillingham, UK) to give 12 fractions by elution with
hexane, chloroform and chloroform–methanol mixtures. Fractions
6, 7 and 8 eluted with 30% hexane and in chloroform were com-
bined yielding pure compound 1 (94 mg). The chloroform extract
(8.3 g) was  fractionated by VLC with an increasingly polar gradi-
ent of 10% from 100% hexane to 100% ethyl acetate, yielding 12
fractions. Fractions 6 and 7 showing a similar TLC proﬁle were com-
bined (2.5 g) and were further separated using Sephadex column
chromatography using the same method described above. Frac-
tions 2 and 3 eluted with 35% hexane in chloroform from Sephadex
were combined (160 mg)  and further separated by preparative TLC
silica plates (20 mm × 20 mm,  60F254; Merck) using hexane–ethyl
acetate–acetic acid (85:15:2) to give compound 2 (25 mg).
2.2.1. Compound 1 (hypercalin B)
Pale yellow amorphous solid. Electrospray ionisation mass
spectrometry (ESI-MS) [M+H]+ m/z 519, calculated for C33H43O5.
Ultraviolet (UV) (CHCl3) max (log ε): 360 (4.09), 285 (3.56), 244
(3.81) nm.  Infrared (IR) vapour maximum (Vmax thin ﬁlm) cm−1:
(3370, 3060, 2960, 2920, 28 260). Proton (1H) and carbon (13C)
nuclear magnetic resonance (NMR) spectroscopic data were in
close agreement with those of hypercalin B isolated from Hypericum
calycinum [20].
2.2.2.  Compound 2 (hyperenone A)
Yellow oil. High-resolution ESI-MS [M+H]+ m/z 271.1396 calcu-
lated for C17H19O3. UV (CHCl3) max (log ε): 236 (4.12), 276 (4.07)
nm. IR Vmax (thin ﬁlm) cm−1: (1651, 1614, 1580). 1H and 13C NMR
spectroscopic data (Table 1).
2.3. Structure elucidation
One-dimensional (1D) and two-dimensional (2D) NMR  spec-
tra were recorded on an Avance 500 MHz  spectrometer (Bruker,
Coventry, UK). Chemical shift values (ı) were reported in parts per
million (ppm). Samples were dissolved in deuterated chloroform.
IR spectra were recorded on a Nicolet 360 FT-IR spectrophotometer
(Thermo Fisher Scientiﬁc, Loughborough, UK), and UV spectra on a
Thermo Electron Corporation Helios spectrophotometer (Thermo
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isher Scientiﬁc). Mass spectra were recorded on a Micromass Q-
OF Global Tandem Mass Spectrometer (Waters Corp., Manchester,
K).
.4. Minimum inhibitory concentration (MIC) determination
gainst Staphylococcus aureus
Prior to antibacterial bioassay, strains were subcultured freshly
n Mueller–Hinton agar medium (Oxoid Ltd., Basingstoke, UK) and
ncubated for 24 h at 37 ◦C prior to MIC  determination. Control
ntibiotics norﬂoxacin, tetracycline, vancomycin, erythromycin
nd ciproﬂoxacin were also used. Mueller–Hinton broth (Oxoid
td.) was adjusted to contain 20 mg/L Ca2+ and 10 mg/L Mg2+. An
noculum density of 5 × 105 colony-forming units/mL of each S.
ureus strain was prepared in normal saline (9 g/L) by comparison
ith a 0.5 McFarland turbidity standard. The inoculum (125 L)
as added to all wells of a microtitre plate and the plate was
ncubated at 37 ◦C for 18 h. For MIC  determination, 20 L of a
 mg/mL  methanolic solution of 3-(4,5-dimethylthiazol-2-yl)-2,5-
iphenyltetrazolium bromide (MTT) was added to each of the wells
nd was incubated for 20 min. Bacterial growth was  indicated by a
olour change from yellow to dark blue. The MIC  was  recorded as
he lowest concentration at which no growth was observed.
.5.  Minimum inhibitory concentration determination against
ycobacteria
Mycobacterium bovis BCG was grown at 37 ◦C in an incuba-
or in 100 mL  of Middlebrook 7H9 broth medium supplemented
ith 10% (v/v) albumin–dextrose–catalase (Difco, Oxford, UK) and
.05% Tween 80 in roller bottles with rotation at 2 rpm until
id-exponential phase [optical density at 600 nm (OD600) = 1.0].
ycobacterium tuberculosis H37Rv was grown at 37 ◦C in an
ncubator as a standing culture in 30 mL  universals in Middle-
rook 7H9 broth medium supplemented with 10% (v/v) oleic
cid–albumin–dextrose–catalase (OADC) (Difco) and 0.05% Tween
0 until mid-exponential phase (1 McFarland turbidity standard).
For  quality control of the mycobacterial cultures, M. bovis
CG was stained with a modiﬁed Ziehl–Neelsen staining protocol
sing a Tb-color kit (Bund Deutscher Hebammen Laboratory, Karl-
ruhe, Germany) according to the manufacturer’s procedure, and M.
uberculosis H37Rv was grown on a blood agar plate to detect con-
amination. MICs against mycobacteria were determined using the
pot culture growth inhibition assay as described previously [21].
n aliquot of 5 mL  of Middlebrook 7H10 (BD Biosciences, Oxford,
K) supplemented with 0.2% glycerol and 10% OADC was  added to
 six-well plate along with compounds at concentrations of 100,
5, 50, 25, 10 and 0 mg/L in a 5 L solution of dimethyl sulphoxide
DMSO). Afterwards, 5 L of an appropriately diluted mid-log phase
f 105 cells/mL was carefully dispensed into the centre of each well.
 well with no compound containing 0.1% DMSO was used as a neg-
tive control. The MIC  was determined after 2 weeks of incubation
t 37 ◦C. A frontline antitubercular drug, isoniazid (INH), was  also
sed as a positive control.
.6.  Escherichia coli JM109 killing curves
A seed culture of E. coli JM109 was grown up to mid-log phase
OD600 = 1.9). Then, 1 mL  of the seed culture was mixed with 100 mL
f fresh Luria–Bertani medium and 5 mL  was distributed into 25-
L volume glass culture tubes (Brand GmbH, Wertheim, Germany)
ontaining either the inhibitors used in this study (ﬁnal concentra-
ion 200 mg/L) or DMSO (ﬁnal concentration 0.1%). These cultures
ere then grown at 37 ◦C in a shaking incubator rotating at 180 rpm.
he glass tubes were placed into the cell holder of a spectropho-
ometer (Biochrom WPA  CO8000; Biochrom, Cambridge, UK) andimicrobial Agents 39 (2012) 124– 129
the OD600 was  measured every 30 min  until the culture reached
stationary phase. INH was taken as a positive control and the exper-
iment was  performed in triplicate.
2.7. Cytotoxicity assay
Mouse  macrophage cells (RAW 264.7) were cultured in 5 mL of
complete RPMI 1640 medium supplemented with 10% foetal bovine
serum and 1% l-glutamine in a 25 cm2 vented, screw-cap cell cul-
ture ﬂask (Flowgen Bioscience Ltd., Hessle, UK)  and incubated at
37 ◦C with a supply of 5% CO2. For use in cytotoxicity assay, cells
were detached using 5 mL  of lidocaine–ethylene diamine tetra-
acetic acid (EDTA) for 10 min at room temperature, followed by
banging the side of the ﬂask against the palm of the hand, and
diluted with an equal volume of fresh media. Cells were then
centrifuged at 1000 rpm for 5 min  at room temperature, washed
twice with 1× phosphate-buffered saline, re-suspended in com-
plete RPMI media, counted and diluted to adjust to 105 cells/mL.
Then, 100 L of cells were seeded to each well of a 96-well plate
containing ﬁnal concentrations (3.125–200 mg/L) of inhibitors and
controls that had been pre-plated by serial dilution [22]. DMSO
and INH were used as negative and positive controls, respectively,
and the experiment was performed in triplicate. Following 48 h of
incubation at 37 ◦C in 5% CO2, medium was  replaced and supple-
mented with 30 L of freshly prepared 0.01% resazurin solution. A
change in colour from blue to pink indicating the viability of cells
was observed after 16 h incubation at 37 ◦C in 5% CO2. For quantita-
tive analysis, the ﬂuorescence intensity was measured by excitation
at 560 nm and emission at 590 nm using a ﬂuorescence microtitre
plate reader (BMG Labtech GmbH, Ortenberg, Germany).
2.8.  Inhibition of ATP-dependent MurE ligase activity from
Mycobacterium tuberculosis
The  MurE enzyme activity assay [11] was  set up using 100 ng of
MurE enzyme in the presence of 25 mM  Bis–Tris–propane/HCl (pH
8.5), 5 mM MgCl2, 250 M ATP, 100 M UDP-MurNAc-l-Ala–d-Glu
and  4% DMSO (enzyme reaction) at 37 ◦C. The compounds were
dissolved in DMSO at concentrations of 100, 500 and 1000 M.
The reaction was initiated by the addition of 1 mM m-DAP. After
30 min, 12.5 L of gold-lock reagent with accelerator was  added
to terminate the reaction. After 5 min, a stabiliser was  added and
the reaction was left for 30 min  at room temperature (25 ◦C) for
colour development. The assay was performed in a ﬁnal volume
of 50 L in a half-area Costar microtitre plate (Applied Biosystems,
Carlsbad, CA). Inorganic phosphate binds to the gold-lock reagent
to form a complex with an absorption maximum of 635 nm. MurE
activity was estimated through phosphate release by measuring
the absorbance of the reaction mixtures at 635 nm after 30 min.
Absorbance values were corrected for background absorbance of
the reaction mixtures and for any non-enzymatic hydrolysis of ATP
in the absence of the enzyme (control reaction). Percent inhibition
was calculated using a negative control (0%) and enzyme reaction
(100% activity). All assays were performed in triplicate.
3.  Results
3.1. Structural elucidation of compounds
Examination of the 13C spectra of compound 1 revealed similar-
ities with other hypercalin derivatives previously isolated from H.
calycinum, and the NMR  data were in good agreement with those of
hypercalin B [20]. Compound 2 was  obtained as a yellow oil whose
molecular formula was  C17H18O3 as established by high-resolution
mass spectrometry showing an [M+H]+ ion at m/z 271.1396. Its IR
spectrum indicated the presence of a carbonyl (1651 cm−1) and
K. Osman et al. / International Journal of Antimicrobial Agents 39 (2012) 124– 129 127
Table  2
Minimum inhibitory concentrations (MICs) of compounds and control antibiotics against Staphylococcus aureus strains.
Agent MIC  (mg/L)
SA-1199B EMRSA-15 EMRSA-16 RN4220 XU212 ATCC 25923
Compound 1 0.5 128 64 16 2 16
Compound  2 2 64 128 32 32 16
Norﬂoxacin  32 1 256 0.5 16 2
0.25 0.25 64 0.25
>128 64 >128 0.25
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enzene ring (1614 and 1580 cm−1), which was conﬁrmed by the
3C NMR  data (Table 1). The 13C NMR  spectra exhibited 17 signals,
hich by 1H NMR  and 13C Dept-135 experiments corresponded
o six quaternary carbons, seven methines, one methylene, two
ethyls and one methoxy group. Five aromatic hydrogens at ı
.70 m,  7.48 m and 7.47 m in the 1H NMR  spectrum (Table 1) indi-
ated the presence of a monosubstituted benzene ring. The 1H and
3C resonances of this moiety were assigned by close inspection of
he heteronuclear multiple quantum coherence (HMQC) spectrum
s ı 7.70 (H-2′, 6′) with ı 125.4 (C-2′, 6′), ı 7.48 (H-3′, 5′) with ı
29.3 (C-5′) and ı 7.47 (H-4′) with ı 131.0 (C-4′). Careful analysis
f the heteronuclear multiple bond coherence (HMBC) spectrum
evealed that the aromatic singlet at ı 6.61 (H-5) showed a 2J cor-
elation to the carbonyl at 181.4 (C-4), a quaternary carbon at 157.1
C-2) and a 3J correlation to the quaternary carbons at 111.5 (C-5)
nd 131.1 (C-1′).
This  indicated that the aromatic ring was attached to a ben-
ene ring at C-1′. The signals at 4.90 (1H, dd, 13.5, 0.5 Hz) and 1.50
6-H) were indicative of a 1,1-dimethylprop-2-enyl side chain in
he molecule. The assignment of all 1H and 13C resonances as well
s the moiety of the attachment of 1,1-dimethylprop-2-enyl side
hain at C-2 was achieved by the HMBC experiment. In addition, a
ethoxy group at ı 4.06 demonstrated a 3J correlation to a quater-
ary carbon at 162.9 and conﬁrmed its placement at C-3. These data
ogether with analysis of the COSY spectrum revealed compound
 to be hyperenone A (Fig. 1), which was previously isolated from
ypericum mysorense Heyne, but its 13C data were not reported [23].
ere we publish the 13C NMR  data for hyperenone A for the ﬁrst
ime based on extensive 1D- and 2D-NMR experiments (Table 1)..2. Effect of both compounds on Staphylococcus aureus
Compounds 1 and 2 were tested for their ability to inhibit
he growth of S. aureus strains. Both of the compounds showed
ig. 2. Effect of compound 2 on the growth of mycobacterial species using a spot culture g
erium tuberculosis H37Rv cells were spotted on solidiﬁed Middlebrook 7H10 agar contain
sing  a digital camera after 14 days of inoculation.1 2
Fig. 1. Structures of hypercalin B (1) and hyperenone A (2).
signiﬁcant antibacterial activity, with a range of MIC  values from
0.5 mg/L to 128 mg/L (Table 2).
3.3.  Growth inhibition of Mycobacterium spp.
Both compounds were evaluated for their antibacterial activity
against M. tuberculosis H37Rv and M. bovis BCG on solid agar media
at different concentrations (10, 25, 50, 75 and 100 mg/L) in a six-
well plate. Compound 1 was  found to be inactive for both species,
whilst compound 2 was  active with MIC  values >75 mg/L for both
species. At 100 mg/L, compound 2 showed complete growth inhibi-
tion, whereas at 75 mg/L reduced growth was  observed compared
with the negative control (Fig. 2).
3.4. Escherichia coli JM109 killing curvesTo evaluate whether the compounds’ selectivity affected slow-
growing mycobacteria in comparison with fast-growing bacteria,
whole-cell experiments were carried out. Comparative time mea-
surement of E. coli growth after exposure to a high concentration of
rowth inhibition assay. Approximately 500 Mycobacterium bovis BCG and Mycobac-
ing different concentrations of compound 2 in a six-well plate. Pictures were taken
128 K. Osman et al. / International Journal of Ant
Fig. 3. Effect of compound 2 on MurE enzyme activity. The x-axis represents the
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tifferent concentrations of the compound tested in the assay and the y-axis repre-
ents the percent inhibition at different concentrations of the compound. The assay
as performed in triplicate.
ompounds, typically 200 mg/L, was determined by measuring the
D600. Compounds 1 and 2 were inactive against Gram-negative
. coli JM109.
.5.  Macrophage RAW 264.7 cytotoxicity
To determine whether the isolated compounds were toxic to
ammalian cells, a cytotoxicity assay using RAW 264.7 cells at
 serially diluted range of assay concentrations (3.125–200 mg/L)
as performed and the cell viability was calculated. The result
evealed that 100% eukaryotic cell viability was observed either
p to 50 mg/L of compound 1 or up to 100 mg/L of compound 2
Supplementary Fig. 1).
.6. Mycobacterium tuberculosis MurE enzyme inhibition
Inhibition of recombinant M. tuberculosis MurE was assayed
nder different concentrations of isolated compounds using the
olorimetric detection of phosphate, which has been shown to be
toichiometrically coupled to m-DAP ligation [10,24]. Compound 1
id not inhibit MurE, whilst compound 2 showed 7%, 77% and 83%
nhibition at 100, 500 and 1000 M concentrations, respectively,
aving a 50% inhibitory concentration (IC50) of 320 M (Fig. 3).
. Discussion
The Hypericum genus is a valuable source of new phytochemicals
nd antibacterial compounds [13]. Compounds isolated from this
roup of plants have been shown to demonstrate antistaphylococ-
al activity [25,26] as well as many other biological activities such
s antifungal properties [27]. Compound 1, which was  previously
solated from H. calycinum, exhibited in vitro growth inhibitory
ctivity against the Co-115 human colon carcinoma cell line [20].
ompound 2 was previously isolated from H. mysorense. Here we
how for the ﬁrst time signiﬁcant activity of these compounds with
IC  values of 0.5–128 mg/L and 2–128 mg/L, respectively, against
 panel of S. aureus strains, some of which are meticillin-resistant
nd multidrug-resistant (MDR) (Table 2). With the exception of
MRSA-15, compound 1 was slightly more active against all of
he S. aureus strains compared with compound 2. The strains
ncluded SA-1199B, a MDR  strain that overexpresses the NorA
fﬂux mechanism, the best characterised antibiotic pump in this
pecies. SA-1199B also possesses a gyrase mutation that, in addition
o NorA, confers a high level of resistance to certain ﬂuoro-
uinolones. Against this strain, both compound 1 (MIC = 0.5 mg/L)
nd compound 2 (MIC = 2 mg/L) were more active than the con-
rol antibiotic norﬂoxacin (MIC = 32 mg/L). For MDR  strain XU212,imicrobial Agents 39 (2012) 124– 129
which  possesses the Tet(K) efﬂux transporter and is resistant
to both tetracycline and meticillin, compound 1 showed bet-
ter inhibitory activity (MIC = 2 mg/L) compared with the positive
control antibiotics (Table 2). Both compounds 1 and 2 showed mod-
erate activity against a standard S. aureus strain (ATCC 25923) as
well as RN4220, which possesses the MsrA macrolide efﬂux pump,
but were less active than the control antibiotics. Compound 1 was
slightly more active against EMRSA-16 compared with EMRSA-
15, one of the major EMRSA strains occurring in UK hospitals. In
addition, compound 2 (MIC = 2 mg/L) was marginally more active
against SA-1199B than the ﬂuoroquinolone ciproﬂoxacin control
(MIC = 8 mg/L).
The  in vitro antibacterial activity of compounds 1 and 2 did not
inhibit the growth of E. coli and both were non-toxic to mammalian
cells. Compound 2 was evaluated against the pathogenic M. tuber-
culosis H37Rv and the vaccine strain M.  bovis BCG (Fig. 2) and was
shown to be active at 100 mg/L for both species. Compounds with a
higher degree of lipophilicity may  play an important role in antimy-
cobacterial activity. The mycobacterial cell wall contains lipophilic
substances such as mycolic acid, thus lipophilic compounds would
therefore have the advantage of better penetration through the cell
wall to inhibit the growth of mycobacteria.
There is an ongoing effort to ﬁnd inhibitors of Mur  enzymes
involved in peptidoglycan biosynthesis to target different bacte-
rial diseases. Phosphonates, phosphinates and sulphonamides are
amongst the inhibitors of MurC, MurD, MurE and MurF. Sova et al.
[28] evaluated a series of phosphorylated hydroxyethylamines as a
new type of small-molecule inhibitor of Mur  ligases and found that
the IC50 values of these inhibitors were in the micromolar range,
making them a promising starting point for the development of
multiple inhibitors of Mur  ligases as potential antibacterial agents.
Towards identifying the inhibitors of these enzymes, compounds
extracted from H. acmosepalum were tested against MurE of M.
tuberculosis. Of the two compounds tested, compound 2 showed a
good dose-dependent inhibition of MurE enzyme activity. Although
the precise antibacterial mode of action of compound 2 remains
unknown, it is possible that its activity could be due to MurE
enzyme inhibition. However, this hypothesis needs further inves-
tigation. Availability of the three-dimensional structure of MurE of
M.  tuberculosis facilitates further optimisation of this compound to
improve its potency through fragment-based screening or docking
studies [10,24]. This increases the chance of developing a natural
product into a potential antimycobacterial compound with a novel
mechanism of action.
To  conclude, here we  report the antibacterial activity of com-
pounds 1 and 2 against a panel of S. aureus, M.  tuberculosis H37Rv
and M.  bovis BCG bacteria. In addition, both of the compounds
were non-cytotoxic to mammalian cells. Furthermore, compound 2
demonstrated speciﬁc dose-dependent inhibition of MurE enzyme
activity of M. tuberculosis. As there is a lack of antibacterial com-
pounds targeting Mur  ligase enzymes, further research in this
respect is required. The antibacterial activity of these compounds
represents a promising starting point for further development.
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